Skip to main content
Top
Published in: Breast Cancer Research 4/2004

Open Access 01-08-2004 | Research article

The DNMT3B C→T promoter polymorphism and risk of breast cancer in a British population: a case-control study

Authors: Karen G Montgomery, Mira CP Liu, Diana M Eccles, Ian G Campbell

Published in: Breast Cancer Research | Issue 4/2004

Login to get access

Abstract

Background

Gene promoter methylation is an important regulator of expression and is a key epigenetic factor in tumorigenesis. DNA methylation is mediated by DNA methyltransferases (DNMTs), of which three active forms have been identified: DNMT1, DNM3A and DNMT3B. The C→T transition polymorphism (C46359T) in the promoter of the DNMT3B gene, which significantly increases transcriptional activity, has been postulated to increase the propensity for promoter-hypermethylation-mediated silencing of tumour suppressor genes.

Methods

To determine the role of this polymorphism in breast cancer, we genotyped 352 cases and 258 controls from a British population. The breast cancer cases were selected on the basis of either an age at onset of less than 40 years, a family history of breast cancer irrespective of age at onset, or bilateral breast cancer diagnosed after 39 years of age irrespective of family history.

Results

The C allele was found to be more common in case subjects than in control subjects (cases, 0.59; controls, 0.54) corresponding to a nominally significant increase in breast cancer risk to heterozygotes and CC homozygotes (odds ratio 1.51, 95% confidence interval 1.01–2.25) in the dominant inheritance model.

Conclusions

Our findings contrast with those of a previous study, which showed that individuals carrying at least one T allele have a significantly increased risk of developing lung cancer. This discrepancy might be an artefact resulting from a chance variation, or it might point to differing influences of promoter hypermethylation in these cancer types.
Literature
1.
go back to reference Weber BL, Nathanson KL: Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer. 2000, 36: 1193-1199. 10.1016/S0959-8049(00)00082-4.CrossRefPubMed Weber BL, Nathanson KL: Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer. 2000, 36: 1193-1199. 10.1016/S0959-8049(00)00082-4.CrossRefPubMed
3.
go back to reference Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999, 8: 843-854.PubMed Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999, 8: 843-854.PubMed
4.
go back to reference Coughlin SS, Piper M: Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1999, 10: 1023-1032. Coughlin SS, Piper M: Genetic polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1999, 10: 1023-1032.
5.
go back to reference Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A: Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003, 9: 4396-4403.PubMed Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A: Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003, 9: 4396-4403.PubMed
6.
go back to reference Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A: Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev. 2002, 11: 127-130.PubMed Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A: Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev. 2002, 11: 127-130.PubMed
7.
go back to reference Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J: Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002, 12: 269-272. 10.1097/00008571-200204000-00012.CrossRefPubMed Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J: Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002, 12: 269-272. 10.1097/00008571-200204000-00012.CrossRefPubMed
8.
go back to reference Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, Easton DF, Ponder BA: A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000, 26: 362-364. 10.1038/81691.CrossRefPubMed Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, Easton DF, Ponder BA: A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000, 26: 362-364. 10.1038/81691.CrossRefPubMed
9.
go back to reference Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002, 21: 5427-5440. 10.1038/sj.onc.1205600.CrossRefPubMed Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002, 21: 5427-5440. 10.1038/sj.onc.1205600.CrossRefPubMed
10.
go back to reference Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-428. 10.1038/nrg962.CrossRefPubMed Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-428. 10.1038/nrg962.CrossRefPubMed
11.
go back to reference Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q: A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002, 62: 4992-4995.PubMed Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q: A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002, 62: 4992-4995.PubMed
12.
go back to reference Clark SJ, Melki J: DNA methylation and gene silencing in cancer: which is the guilty party?. Oncogene. 2002, 21: 5380-5387. 10.1038/sj.onc.1205598.CrossRefPubMed Clark SJ, Melki J: DNA methylation and gene silencing in cancer: which is the guilty party?. Oncogene. 2002, 21: 5380-5387. 10.1038/sj.onc.1205598.CrossRefPubMed
13.
go back to reference Yakushiji T, Uzawa K, Shibahara T, Noma H, Tanzawa H: Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol. 2003, 22: 1201-1207.PubMed Yakushiji T, Uzawa K, Shibahara T, Noma H, Tanzawa H: Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol. 2003, 22: 1201-1207.PubMed
14.
go back to reference Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S: Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer. 2003, 105: 527-532. 10.1002/ijc.11127.CrossRefPubMed Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S: Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer. 2003, 105: 527-532. 10.1002/ijc.11127.CrossRefPubMed
15.
go back to reference Patra SK, Patra A, Zhao H, Dahiya R: DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog. 2002, 33: 163-171. 10.1002/mc.10033.CrossRefPubMed Patra SK, Patra A, Zhao H, Dahiya R: DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog. 2002, 33: 163-171. 10.1002/mc.10033.CrossRefPubMed
16.
go back to reference Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001, 97: 1172-1179. 10.1182/blood.V97.5.1172.CrossRefPubMed Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001, 97: 1172-1179. 10.1182/blood.V97.5.1172.CrossRefPubMed
17.
go back to reference Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA: The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999, 27: 2291-2298. 10.1093/nar/27.11.2291.CrossRefPubMedPubMedCentral Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA: The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999, 27: 2291-2298. 10.1093/nar/27.11.2291.CrossRefPubMedPubMedCentral
18.
go back to reference Wang L, Liu Z, Mao L, Spitz MR, Wei Q: Functional relevance of C46359T in the promoter region of human DNMT3B6 [Abstract]. Proc AACR. 2004, 45: 2913- Wang L, Liu Z, Mao L, Spitz MR, Wei Q: Functional relevance of C46359T in the promoter region of human DNMT3B6 [Abstract]. Proc AACR. 2004, 45: 2913-
19.
go back to reference Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, Hasegawa Y: The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene. 2002, 21: 4822-4829. 10.1038/sj.onc.1205581.CrossRefPubMed Sato M, Horio Y, Sekido Y, Minna JD, Shimokata K, Hasegawa Y: The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene. 2002, 21: 4822-4829. 10.1038/sj.onc.1205581.CrossRefPubMed
20.
go back to reference Luk C, Tsao MS, Bayani J, Shepherd F, Squire JA: Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet. 2001, 125: 87-99. 10.1016/S0165-4608(00)00363-0.CrossRefPubMed Luk C, Tsao MS, Bayani J, Shepherd F, Squire JA: Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet. 2001, 125: 87-99. 10.1016/S0165-4608(00)00363-0.CrossRefPubMed
23.
go back to reference Soejima K, Fang W, Rollins BJ: DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene. 2003, 22: 4723-4733. 10.1038/sj.onc.1206510.CrossRefPubMed Soejima K, Fang W, Rollins BJ: DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene. 2003, 22: 4723-4733. 10.1038/sj.onc.1206510.CrossRefPubMed
24.
go back to reference Hazra A, Gu J, Zhu Y, Grossman HB, Spitz MR, Wu X: DNMT3b and bladder cancer risk: from genotype to phenotype [Abstract]. Proc AACR. 2004, 45: 1604- Hazra A, Gu J, Zhu Y, Grossman HB, Spitz MR, Wu X: DNMT3b and bladder cancer risk: from genotype to phenotype [Abstract]. Proc AACR. 2004, 45: 1604-
Metadata
Title
The DNMT3B C→T promoter polymorphism and risk of breast cancer in a British population: a case-control study
Authors
Karen G Montgomery
Mira CP Liu
Diana M Eccles
Ian G Campbell
Publication date
01-08-2004
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2004
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr807

Other articles of this Issue 4/2004

Breast Cancer Research 4/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine